---
http_interactions:
- request:
    method: get
    uri: https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=20104584&retmode=xml
    body:
      encoding: ASCII-8BIT
      string: ''
    headers:
      Accept:
      - application/xml
      Connection:
      - close
      Host:
      - eutils.ncbi.nlm.nih.gov
      User-Agent:
      - http.rb/5.2.0
  response:
    status:
      code: 200
      message: OK
    headers:
      Date:
      - Thu, 25 Apr 2024 20:57:12 GMT
      Server:
      - Finatra
      Strict-Transport-Security:
      - max-age=31536000; includeSubDomains; preload
      Content-Security-Policy:
      - upgrade-insecure-requests
      Referrer-Policy:
      - origin-when-cross-origin
      Ncbi-Sid:
      - 95B41A40C6067E98_3C31SID
      Ncbi-Phid:
      - D0BD53D6E3E178B5000054E09B33D036.1.1.m_3
      Content-Type:
      - text/xml; charset=UTF-8
      Cache-Control:
      - private
      X-Ratelimit-Limit:
      - '3'
      X-Ratelimit-Remaining:
      - '2'
      Access-Control-Allow-Origin:
      - "*"
      Access-Control-Expose-Headers:
      - X-RateLimit-Limit,X-RateLimit-Remaining
      Set-Cookie:
      - ncbi_sid=95B41A40C6067E98_3C31SID; domain=.nih.gov; path=/; expires=Fri, 25
        Apr 2025 20:57:12 GMT
      Vary:
      - Accept-Encoding
      X-Ua-Compatible:
      - IE=Edge
      X-Xss-Protection:
      - 1; mode=block
      Connection:
      - close
      Transfer-Encoding:
      - chunked
    body:
      encoding: UTF-8
      string: |-
        <?xml version="1.0" ?>
        <!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
        <PubmedArticleSet>
        <PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20104584</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1098-1004</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Human mutation</Title><ISOAbbreviation>Hum Mutat</ISOAbbreviation></Journal><ArticleTitle>Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study.</ArticleTitle><Pagination><StartPage>E1200</StartPage><EndPage>E1240</EndPage><MedlinePgn>E1200-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/humu.21202</ELocationID><Abstract><AbstractText>BRCA1 and BRCA2 screening in women at high-risk of breast cancer results in the identification of both unambiguously defined deleterious mutations and sequence variants of unknown clinical significance (VUS). We examined a population-based sample of young women with contralateral breast cancer (CBC, n=705) or unilateral breast cancer (UBC, n=1398). We identified 470 unique sequence variants, of which 113 were deleterious mutations. The remaining 357 VUS comprised 185 unique missense changes, 60% were observed only once, while 3% occurred with a frequency of &gt;10%. Deleterious mutations occurred three times more often in women with CBC (15.3%) than in women with UBC (5.2%), whereas combined, VUS were observed in similar frequencies in women with CBC and UBC. A protein alignment algorithm defined 16 rare VUS, occurring at highly conserved residues and/or conferring a considerable biochemical difference, the majority located in the BRCA2 DNA-binding domain. We confirm a multiplicity of BRCA1 and BRCA2 VUS that occur at a wide range of allele frequencies. Although some VUS inflict chemical differences at conserved residues, suggesting a deleterious effect, the majority are not associated with an increased risk of CBC.</AbstractText><CopyrightInformation>(c) 2010 Wiley-Liss, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Borg</LastName><ForeName>Ake</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Oncology, Clinical Sciences, Lund University, Lund, Sweden. ake.borg@med.lu.se</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haile</LastName><ForeName>Robert W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Malone</LastName><ForeName>Kathleen E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Capanu</LastName><ForeName>Marinela</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Diep</LastName><ForeName>Ahn</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>T&#xf6;rngren</LastName><ForeName>Therese</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Teraoka</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Begg</LastName><ForeName>Colin B</ForeName><Initials>CB</Initials></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Duncan C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Concannon</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Mellemkjaer</LastName><ForeName>Lene</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Leslie</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Tellhed</LastName><ForeName>Lina</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Shanyan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Olson</LastName><ForeName>Eric R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Xiaolin</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Dolle</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>B&#xf8;rresen-Dale</LastName><ForeName>Anne-Lise</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Jonine L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA131010</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA097397</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA097397-05</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA131010-02</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA098438</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA097397</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA129639</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA098438</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>CA131010</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG014358</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA098438-03</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Mutat</MedlineTA><NlmUniqueID>9215429</NlmUniqueID><ISSNLinking>1059-7794</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051017">Apoptosis Regulatory Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C118024">BLID protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019313">BRCA1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492913">BRCA1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024682">BRCA2 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C551750">BRCA2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051017" MajorTopicYN="N">Apoptosis Regulatory Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019313" MajorTopicYN="N">BRCA1 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024682" MajorTopicYN="N">BRCA2 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017353" MajorTopicYN="N">Gene Deletion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20104584</ArticleId><ArticleId IdType="mid">NIHMS220427</ArticleId><ArticleId IdType="pmc">PMC2928257</ArticleId><ArticleId IdType="doi">10.1002/humu.21202</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abkevich V, Zharkikh A, Deffenbaugh AM, Frank D, Chen Y, Shattuck D, Skolnick MH, Gutin A, Tavtigian SV. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet. 2004;41:492&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1735826</ArticleId><ArticleId IdType="pubmed">15235020</ArticleId></ArticleIdList></Reference><Reference><Citation>Begg CB, Haile RW, Borg A, Malone KE, Concannon P, Thomas DC, Langholz B, Bernstein L, Olsen JH, Lynch CF Anton-Culver H, Capanu M, Liang X, Hummer AJ, Sima C, Bernstein JL. Variation of breast cancer risk among BRCA1/2 carriers. JAMA. 2008;299:194&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714486</ArticleId><ArticleId IdType="pubmed">18182601</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein JL, Langholz B, Haile RW, Bernstein L, Thomas DC, Stovall M, Malone KE, Lynch CF, Olsen JH, Anton-Culver H, Shore RE, Boice JD, Jr, Berkowitz GS, Gatti RA, Teitelbaum SL, Smith SA, Rosenstein BS, B&#xf8;rresen-Dale AL, Concannon P, Thompson WD WECARE study. Study design: evaluating gene-environment interactions in the etiology of breast cancer &#x2013; WECARE Study. Breast Cancer Res. 2004;6:R199&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC400669</ArticleId><ArticleId IdType="pubmed">15084244</ArticleId></ArticleIdList></Reference><Reference><Citation>Bignell G, Micklem G, Stratton MR, Ashworth A, Wooster R. The BRC repeats are conserved in mammalian BRCA2 proteins. Hum Mol Genet. 1997;6:53&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">9002670</ArticleId></ArticleIdList></Reference><Reference><Citation>Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999;22:231&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391209</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho MA, Couch FJ, Monteiro AN. Functional assays for BRCA1 and BRCA2. Int J Biochem Cell Biol. 2007;39:298&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1862449</ArticleId><ArticleId IdType="pubmed">16978908</ArticleId></ArticleIdList></Reference><Reference><Citation>Chenevix-Trench G, Healey S, Lakhani S, Waring P, Cummings M, Brinkworth R, Deffenbaugh AM, Burbidge LA, Pruss D, Judkins T, Scholl T, Bekessy A, Marsh A, Lovelock P, Wong M, Tesoriero A, Renard H, Southey M, Hopper JL, Yannoukakos K, Brown M, Easton D, Tavtigian SV, Goldgar D, Spurdle AB kConFab Investigators. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res. 2006;66:2019&#x2013;2027.</Citation><ArticleIdList><ArticleId IdType="pubmed">16489001</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti E, Izaurralde E. Nonsense-mediated mRNA decay: molecular insights and mechanistic variations across species. Curr Opin Cell Biol. 2005;17:316&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">15901503</ArticleId></ArticleIdList></Reference><Reference><Citation>den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat. 2000;15:7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">10612815</ArticleId></ArticleIdList></Reference><Reference><Citation>Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, Tavtigian SV, Monteiro AN, Iversen ES, Couch FJ, Goldgar DE. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet. 2007;81:873&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265654</ArticleId><ArticleId IdType="pubmed">17924331</ArticleId></ArticleIdList></Reference><Reference><Citation>Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, Seal S, Hamoudi R, Van Rensburg EJ, Dunning AM, Love R, Evans G, Easton D, Clayton D, Stratton MR, Ponder BA. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet. 1995;11:428&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">7493024</ArticleId></ArticleIdList></Reference><Reference><Citation>Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, Stratton MR, Easton D. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet. 1997;15:103&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">8988179</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet. 2004;75:535&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1182042</ArticleId><ArticleId IdType="pubmed">15290653</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammet F, George J, Tesoriero AA, Jenkins MA, Schroen C, Smith L, Grabosch-Meehan A, Dite G, McCredie MR, Giles GG, Tavtigian SV, Hopper JL, Southey MC. Is BRCA2 c.9079 G &gt; A a predisposing variant for early onset breast cancer? Breast Cancer Res Treat. 2008;109:177&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">17549625</ArticleId></ArticleIdList></Reference><Reference><Citation>Healey CS, Dunning AM, Teare MD, Chase D, Parker L, Burn J, Chang-Claude J, Mannermaa A, Kataja V, Huntsman DG, Pharoah PD, Luben RN, Easton DF, Ponder BA. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet. 2000;26:362&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">11062481</ArticleId></ArticleIdList></Reference><Reference><Citation>Judkins T, Hendrickson BC, Deffenbaugh AM, Eliason K, Leclair B, Norton MJ, Ward BE, Pruss D, Scholl T. Application of embryonic lethal or other obvious phenotypes to characterize the clinical significance of genetic variants found in trans with known deleterious mutations. Cancer Res. 2005;65:10096&#x2013;10103.</Citation><ArticleIdList><ArticleId IdType="pubmed">16267036</ArticleId></ArticleIdList></Reference><Reference><Citation>Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, Jensen RA. Growth retardation and tumour inhibition by BRCA1. Nat Genet. 1996;12:298&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">8589721</ArticleId></ArticleIdList></Reference><Reference><Citation>Kryukov GV, Pennacchio LA, Sunyaev SR. Most rare missense alleles are deleterious in humans: implications for complex disease and association studies. Am J Hum Genet. 2007;80:727&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1852724</ArticleId><ArticleId IdType="pubmed">17357078</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuznetsov SG, Liu P, Sharan SK. Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2. Nat Med. 2008;14:875&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2640324</ArticleId><ArticleId IdType="pubmed">18607349</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone KE, Begg CB, Haile RW, Borg A, Concannon PJ, Tellhed L, Xue S, Teraoka S, Bernstein L, Capanu M, Reiner A, Riedel ER, Thomas DC, Mellemkjaer L, Lynch CF, Boice JD, Anton-Culver H, Bernstein JL. A population-based study of the relative and absolute risks of contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2: Results from the WECARE Study. 2009 Submitted.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2881721</ArticleId><ArticleId IdType="pubmed">20368571</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazoyer S, Dunning AM, Serova O, Dearden J, Puget N, Healey CS, Gayther SA, Mangion J, Stratton MR, Lynch HT, Goldgar DE, Ponder BA, Lenoir GM. A polymorphic stop codon in BRCA2. Nat Genet. 1996;14:253&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">8896551</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JR, Pangon L, Boutell C, Katagiri T, Keep NH, Solomon E. Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. Hum Mol Genet. 2006;15:599&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">16403807</ArticleId></ArticleIdList></Reference><Reference><Citation>Olopade OI, Fackenthal JD, Dunston G, Tainsky MA, Collins F, Whitfield-Broome C. Breast cancer genetics in African Americans. Cancer. 2003;97(Suppl):236&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">12491487</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Mazoyer S. The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet. 2002;11:2805&#x2013;2814.</Citation><ArticleIdList><ArticleId IdType="pubmed">12393792</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully R, Ganesan S, Vlasakova K, Chen J, Socolovsky M, Livingston DM. Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell. 1999;4:1093&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">10635334</ArticleId></ArticleIdList></Reference><Reference><Citation>Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet. 2008;40:17&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">18163131</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, Zharkikh A, Thomas A. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet. 2006;43:295&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2563222</ArticleId><ArticleId IdType="pubmed">16014699</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomassen M, Hansen TV, Borg A, Lianee HT, Wikman F, Pedersen IS, Bisgaard ML, Nielsen FC, Kruse TA, Gerdes AM. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer. Acta Oncol. 2008;47:772&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pubmed">18465347</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson D, Easton D Breast Cancer Linkage Consortium. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet. 2001;68:410&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1235274</ArticleId><ArticleId IdType="pubmed">11170890</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson D, Easton D. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomark Prev. 2002;11:329&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">11927492</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallon-Christersson J, Cayanan C, Haraldsson K, Loman N, Bergthorsson JT, Br&#xf8;ndum-Nielsen K, Gerdes AM, M&#xf8;ller P, Kristoffersson U, Olsson H, Borg A, Monteiro AN. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet. 2001;10:353&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4756649</ArticleId><ArticleId IdType="pubmed">11157798</ArticleId></ArticleIdList></Reference><Reference><Citation>Vega A, Campos B, Bressac-De-Paillerets B, Bond PM, Janin N, Douglas FS, Domenech M, Baena M, Pericay C, Alonso C, Carracedo A, Baiget M, Diez O. The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat. 2001;17:520&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">11385711</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware MD, DeSilva D, Sinilnikova OM, Stoppa-Lyonnet D, Tavtigian SV, Mazoyer S. Does nonsense-mediated mRNA decay explain the ovarian cancer cluster region of the BRCA2 gene? Oncogene. 2006;25:323&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">16170354</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams RS, Glover JN. Structural consequences of a cancer-causing BRCA1-BRCT missense mutation. J Biol Chem. 2003;278:2630&#x2013;2635.</Citation><ArticleIdList><ArticleId IdType="pubmed">12427738</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K, Hinson SR, Ohashi A, Farrugia D, Wendt P, Tavtigian SV, Deffenbaugh A, Goldgar D, Couch FJ. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res. 2005;65:417&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pubmed">15695382</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, Liu X, Jasin M, Couch FJ, Livingston DM. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell. 2006;22:719&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">16793542</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>
  recorded_at: Thu, 25 Apr 2024 20:57:12 GMT
recorded_with: VCR 6.2.0
